Literature DB >> 7527319

Is the development of antibodies to streptokinase clinically relevant?

M B Buchalter1.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7527319     DOI： 10.2165/00003495-199448020-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  11 in total

1.  Antistreptokinase titres after intravenous streptokinase.

Authors:  S Jalihal; G K Morris
Journal:  Lancet       Date:  1990-01-27       Impact factor: 79.321

2.  Anti-streptokinase antibodies inhibit fibrinolytic effects of anistreplase in acute myocardial infarction.

Authors:  J Brügemann; J van der Meer; V J Bom; W van der Schaaf; P A de Graeff; K I Lie
Journal:  Am J Cardiol       Date:  1993-08-15       Impact factor: 2.778

3.  Clinical failure of streptokinase due to an unsuspected high titer of antistreptokinase antibody.

Authors:  A S Lew; T Neer; L Rodriguez; I L Geft; P K Shah; W Ganz
Journal:  J Am Coll Cardiol       Date:  1984-07       Impact factor: 24.094

4.  Thrombolytic therapy with streptokinase using a standard dosage scheme.

Authors:  M Verstraete; J Vermylen; A Amery; C Vermylen
Journal:  Br Med J       Date:  1966-02-19

5.  Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction.

Authors:  R Fears; J Hearn; R Standring; J L Anderson; V J Marder
Journal:  Am Heart J       Date:  1992-08       Impact factor: 4.749

6.  Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction.

Authors:  S Patel; S Jalihal; D P Dutka; G K Morris
Journal:  Br Heart J       Date:  1993-08

7.  Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG.

Authors:  R Fears; H Ferres; E Glasgow; R Standring; K J Hogg; J D Gemmill; J M Burns; A P Rae; F G Dunn; W S Hillis
Journal:  Br Heart J       Date:  1992-08

8.  Immunoglobulin response to intravenous streptokinase in acute myocardial infarction.

Authors:  M Lynch; W A Littler; B L Pentecost; R A Stockley
Journal:  Br Heart J       Date:  1991-08

9.  Streptokinase resistance: when might streptokinase administration be ineffective?

Authors:  M B Buchalter; G Suntharalingam; I Jennings; C Hart; R J Luddington; R Chakraverty; S K Jacobson; P L Weissberg; T P Baglin
Journal:  Br Heart J       Date:  1992-11

10.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321
View more
  2 in total

Review 1.  New peptide and protein drugs.

Authors:  P Vermeij; D Blok
Journal:  Pharm World Sci       Date:  1996-06

Review 2.  Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?

Authors:  J Brügemann; P A de Graeff; J van der Meer; K I Lie
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.